Teva Ceases Oral Copaxone Development
This article was originally published in The Pink Sheet Daily
Executive Summary
The company said it is still considering development of “various non-parenteral formulations” for the MS therapy.
You may also be interested in...
Following Phase II Failure, Teva Drops Investigation Of Glatiramer For ALS
Compound fails to meet primary and secondary trial endpoints.
Following Phase II Failure, Teva Drops Investigation Of Glatiramer For ALS
Compound fails to meet primary and secondary trial endpoints.
Teva/Active Biotech Initiate Phase III Program For Laquinimod Oral MS Therapy
Firm enters Phase III along with Acorda, Biogen Idec, others in race to bring first oral MS agent to market.